SIGA (SIGA) Q2 Revenue Soars 272%
SIGA Technologies (NASDAQ:SIGA), a pharmaceutical company known for its antiviral therapies used in biodefense, posted second quarter fiscal 2025 financial results on August 5, 2025. The most striking news from the release was a dramatic jump in GAAP revenue and profitability, spurred by major deliveries of TPOXX antiviral therapies to U.S. government agencies. GAAP revenues reached $81.1 million, sharply up from $21.8 million for Q2 2024. Operating income climbed to $45.7 million, and Net income (GAAP) was $35.5 million. The period featured a marked improvement in margins and balance sheet strength. Overall, the period was defined by expanded cash reserves and a material capital return through a special dividend.
SIGA Technologies is a specialty pharmaceutical company that develops and sells antiviral medicines focused on biodefense. Its lead product, TPOXX, comes in oral and intravenous (IV) formulations and is designed to treat smallpox and related diseases. Most of SIGA’s revenue is currently tied to contracts with U.S. government agencies that purchase TPOXX for the Strategic National Stockpile, a repository intended for public health emergencies.
The company’s recent priorities include delivering on large-scale government contracts for both the oral and IV versions of TPOXX, advancing development programs for pediatric and postexposure prophylaxis (PEP) formulations, securing regulatory approvals in new markets, and maintaining supply chain resilience. Key factors for ongoing success are SIGA’s ability to renew or expand government procurement, to win regulatory approval abroad, and to protect its intellectual property around TPOXX and related products.
Source Fool.com
